---
title: "CUTIA CU-40104 for the treatment of androgenetic alopecia has received implied approval from the mainland drug regulatory authority"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279177818.md"
description: "CUTIA-B announced that its self-developed new drug CU-40104 for the treatment of androgenetic alopecia has received implied approval from the National Medical Products Administration for clinical trial application. CU-40104 is a topical dutasteride medication that can inhibit the conversion of testosterone to dihydrotestosterone in the scalp, which is expected to reduce systemic exposure and side effects. This product will enrich the group's product pipeline for hair diseases and synergize with the already approved CU-40102"
datetime: "2026-03-16T00:19:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279177818.md)
  - [en](https://longbridge.com/en/news/279177818.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279177818.md)
---

# CUTIA CU-40104 for the treatment of androgenetic alopecia has received implied approval from the mainland drug regulatory authority

According to a report from Economic Information Agency on the 16th, CUTIA-B (02487) announced that its self-developed CU-40104 (topical dutasteride formulation) new drug clinical trial (IND) application has received implied approval from the National Medical Products Administration for clinical trials, with the indication for the treatment of androgenetic alopecia.

The company stated that CU-40104 is a topical dutasteride medication. Dutasteride, as a specific competitive inhibitor of type I and II 5α-reductase, can inhibit the conversion of testosterone to dihydrotestosterone in the scalp, thereby treating androgenetic alopecia. The group's developed topical formulation can directly act on the scalp area, which is expected to reduce systemic exposure and related side effects compared to oral dutasteride.

CUTIA pointed out that this product is expected to further enrich the group's product pipeline for hair diseases and complement and synergize with CU-40102 (topical finasteride spray), which has already been approved for marketing by the National Medical Products Administration. (eh)

### Related Stocks

- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)

## Related News & Research

- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [Cutia Therapeutics AGM resolutions passed in shareholder vote](https://longbridge.com/en/news/290935117.md)
- [China closing in but US still leads in biotech innovation, survey finds](https://longbridge.com/en/news/290431706.md)
- [Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio](https://longbridge.com/en/news/285457203.md)